Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced it will report its second quarter 2024 financial results on August 14, 2024, after the U.S. financial markets close. The company will also host a conference call and webcast at 4:30 p.m. ET on the same day to provide a business update. Investors can access the conference call via phone or webcast, with an archived replay available on the company's website afterward. Longeveron focuses on developing cellular therapies for life-threatening and chronic aging-related conditions.
Longeveron Inc. (NASDAQ: LGVN), un'azienda biotecnologica in fase clinica specializzata nella medicina rigenerativa, ha annunciato che presenterà i suoi risultati finanziari del secondo trimestre 2024 il 14 agosto 2024, dopo la chiusura dei mercati finanziari statunitensi. L'azienda ospiterà anche una conferenza telefonica e un webcast alle 16:30 ET dello stesso giorno per fornire un aggiornamento aziendale. Gli investitori possono accedere alla conferenza telefonica tramite telefono o webcast, con una registrazione archiviata disponibile sul sito web dell'azienda successivamente. Longeveron si concentra sullo sviluppo di terapie cellulari per condizioni legate all'invecchiamento cronico e potenzialmente letali.
Longeveron Inc. (NASDAQ: LGVN), una empresa de biotecnología en etapa clínica especializada en medicina regenerativa, ha anunciado que informará sobre sus resultados financieros del segundo trimestre de 2024 el 14 de agosto de 2024, después del cierre de los mercados financieros de EE. UU. La compañía también llevará a cabo una conferencia telefónica y un webcast a las 4:30 p.m. ET ese mismo día para proporcionar una actualización empresarial. Los inversores pueden acceder a la conferencia telefónica por teléfono o webcast, con una grabación archivada disponible en el sitio web de la empresa después. Longeveron se enfoca en desarrollar terapias celulares para condiciones relacionadas con el envejecimiento que amenazan la vida y son crónicas.
Longeveron Inc. (NASDAQ: LGVN), 임상 단계의 재생 의학 생명 공학 회사,는 2024년 2분기 재무 결과를 2024년 8월 14일 미국 금융 시장이 마감된 후 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET에 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다. 투자자들은 전화를 통해 또는 웹캐스트에 접속할 수 있으며, 이후 회사 웹사이트에서 아카이브된 재생 가능 녹음이 제공됩니다. Longeveron은 생명을 위협하는 만성 노화 관련 질환을 위한 세포 요법 개발에 집중하고 있습니다.
Longeveron Inc. (NASDAQ: LGVN), une entreprise de biotechnologie en phase clinique spécialisée dans la médecine régénérative, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 14 août 2024, après la fermeture des marchés financiers aux États-Unis. L'entreprise organisera également une conférence téléphonique et un webcast à 16h30 ET le même jour pour fournir une mise à jour de l'entreprise. Les investisseurs peuvent accéder à la conférence téléphonique par téléphone ou par webcast, une rediffusion archivée sera disponible sur le site web de l'entreprise par la suite. Longeveron se concentre sur le développement de thérapies cellulaires pour des conditions menaçant la vie et des affections chroniques liées au vieillissement.
Longeveron Inc. (NASDAQ: LGVN), ein biotechnologisches Unternehmen im klinischen Stadium für regenerative Medizin, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am 14. August 2024 nach Schließung der US-Finanzmärkte bekannt geben wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um ein Unternehmensupdate zu geben. Investoren können an der Telefonkonferenz via Telefon oder Webcast teilnehmen, mit einem archivierten Replay, das anschließend auf der Website des Unternehmens verfügbar ist. Longeveron konzentriert sich auf die Entwicklung von Zelltherapien für lebensbedrohliche und chronische, altersbedingte Erkrankungen.
- None.
- None.
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
| Conference Call Details: | |
| Conference Call Number: | 1.877.407.0789 |
| Conference ID: | 13747923 |
| Call me™ Feature: | Click Here |
| Webcast: | Click Here |
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s Disease (AD), and Aging-related Frailty. Lomecel-BTM development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When will Longeveron (LGVN) report its Q2 2024 financial results?
What time is Longeveron's (LGVN) Q2 2024 earnings call scheduled for?
How can investors access Longeveron's (LGVN) Q2 2024 earnings call?
What is the main focus of Longeveron's (LGVN) business?
